417 related articles for article (PubMed ID: 26260889)
1. Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes.
Vatankulu B; Yilmaz Aksoy S; Asa S; Sager S; Sayman HB; Halac M; Sonmezoglu K
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):17-21. PubMed ID: 26260889
[TBL] [Abstract][Full Text] [Related]
2. [(18)F-FDG PET/CT in the evaluation of patients suspected of paraneoplastic neurological syndrome].
García Vicente AM; Vega Caicedo CH; Mondéjar Solís R; de Ayala Fernández JÁ; Garrido Robles JA; Pena Pardo FJ; Muñoz Pasadas M; Del Saz Saucedo P; Jiménez Londoño GA; León Martín A; Soriano Castrejón Á
Rev Esp Med Nucl Imagen Mol; 2015; 34(4):236-43. PubMed ID: 25864422
[TBL] [Abstract][Full Text] [Related]
3. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis.
Patel RR; Subramaniam RM; Mandrekar JN; Hammack JE; Lowe VJ; Jett JR
Mayo Clin Proc; 2008 Aug; 83(8):917-22. PubMed ID: 18674476
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
5. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes.
Matsuhisa A; Toriihara A; Kubota K; Makino T; Mizusawa H; Shibuya H
Clin Nucl Med; 2012 Jan; 37(1):39-43. PubMed ID: 22157026
[TBL] [Abstract][Full Text] [Related]
6. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit.
Hadjivassiliou M; Alder SJ; Van Beek EJ; Hanney MB; Lorenz E; Rao DG; Sharrack B; Tindale WB
Acta Neurol Scand; 2009 Mar; 119(3):186-93. PubMed ID: 18855873
[TBL] [Abstract][Full Text] [Related]
7. Multiplex serology of paraneoplastic antineuronal antibodies.
Maat P; Brouwer E; Hulsenboom E; VanDuijn M; Schreurs MW; Hooijkaas H; Smitt PA
J Immunol Methods; 2013 May; 391(1-2):125-32. PubMed ID: 23500780
[TBL] [Abstract][Full Text] [Related]
8. Imaging Workup of Suspected Classical Paraneoplastic Neurological Syndromes: A Systematic Review and Retrospective Analysis of
Sundermann B; Schröder JB; Warnecke T; Heindel W; Schäfers M; Weckesser M; Buerke B
Acad Radiol; 2017 Oct; 24(10):1195-1202. PubMed ID: 28551401
[TBL] [Abstract][Full Text] [Related]
9. "Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected.
Berger B; Bischler P; Dersch R; Hottenrott T; Rauer S; Stich O
J Neurol Sci; 2015 May; 352(1-2):58-61. PubMed ID: 25824848
[TBL] [Abstract][Full Text] [Related]
10.
Harlos C; Metser U; Poon R; MacCrostie P; Mason W
Curr Oncol; 2019 Aug; 26(4):e458-e465. PubMed ID: 31548813
[TBL] [Abstract][Full Text] [Related]
11. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis.
Linke R; Schroeder M; Helmberger T; Voltz R
Neurology; 2004 Jul; 63(2):282-6. PubMed ID: 15277621
[TBL] [Abstract][Full Text] [Related]
12. Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT.
Schramm N; Rominger A; Schmidt C; Morelli JN; Schmid-Tannwald C; Meinel FG; Reiser MF; Rist C
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1014-24. PubMed ID: 23503574
[TBL] [Abstract][Full Text] [Related]
13. Utility of 18F-FDG-PET/CT in patients suspected of paraneoplastic neurological syndrome: importance of risk classification.
Pena Pardo FJ; García Vicente AM; Amo-Salas M; López-Fidalgo JF; Garrido Robles JA; de Ayala Fernández JÁ; Del Saz Saucedo P; Muñoz Pasadas M; Soriano Castrejón A
Clin Transl Oncol; 2017 Jan; 19(1):111-118. PubMed ID: 27139696
[TBL] [Abstract][Full Text] [Related]
14. A large screen for paraneoplastic neurological autoantibodies; diagnosis and predictive values.
Seluk L; Taliansky A; Yonath H; Gilburd B; Amital H; Shoenfeld Y; Kivity S
Clin Immunol; 2019 Feb; 199():29-36. PubMed ID: 30543927
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.
Storstein A; Raspotnig M; Vitaliani R; Giometto B; Graus F; Grisold W; Honnorat J; Vedeler CA
J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485
[TBL] [Abstract][Full Text] [Related]
16. Paraneoplastic antibody during follow-up of a patient with anti-Ri-associated paraneoplastic neurological syndrome.
Stich O; Rasiah C; Rauer S
Acta Neurol Scand; 2009 May; 119(5):338-40. PubMed ID: 18822086
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients.
Kristensen SB; Hess S; Petersen H; Høilund-Carlsen PF
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2056-63. PubMed ID: 26194717
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET-CT in the evaluation of paraneoplastic syndromes: experience at a regional oncology centre.
Vaidyanathan S; Pennington C; Ng CY; Poon FW; Han S
Nucl Med Commun; 2012 Aug; 33(8):872-80. PubMed ID: 22669052
[TBL] [Abstract][Full Text] [Related]
19. Onconeuronal and antineuronal antibodies in patients with neoplastic and non-neoplastic pulmonary pathologies and suspected for paraneoplastic neurological syndrome.
Michalak S; Cofta S; Piatek A; Rybacka J; Wysocka E; Kozubski W
Eur J Med Res; 2009 Dec; 14 Suppl 4(Suppl 4):156-61. PubMed ID: 20156748
[TBL] [Abstract][Full Text] [Related]
20. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
